Physician profile
Kent A Knauer
NPI 1790881258
$1,438.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $247.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $405.38 | 2019-2020 | |
| Pfizer INC. | $165.69 | 2019-2020 | |
| Genzyme Corporation | $159.75 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $157.29 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $129.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $126.35 | 2019 | |
| Csl Behring | $90.90 | 2019 | |
| Optinose US, INC. | $78.34 | 2019-2020 | |
| Genentech USA, INC. | $62.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $21.83 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.09 | 2019 | |
| Mylan Specialty L.P. | $11.79 | 2019 | |
| Shire North American Group INC | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Knauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.